This report contains market size and forecasts of Polycystic Ovary Syndrome (PCOS) Drugs in global, including the following market information:
- Global Polycystic Ovary Syndrome (PCOS) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
- Global Polycystic Ovary Syndrome (PCOS) Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Polycystic Ovary Syndrome (PCOS) Drugs companies in 2021 (%)
The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at 3413.8 million in 2021 and is projected to reach US$ 4550.6 million by 2028, at a CAGR of 4.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Contraceptives Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Polycystic Ovary Syndrome (PCOS) Drugs include Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co. and Ferring Pharmaceuticals, Inc. and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Polycystic Ovary Syndrome (PCOS) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Polycystic Ovary Syndrome (PCOS) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Polycystic Ovary Syndrome (PCOS) Drugs Market Segment Percentages, by Type, 2021 (%)
- Oral Contraceptives
- Antiandrogens
- Insulin-Sensitizing Agent
- Antidepressant
- Anti-Obesity
Global Polycystic Ovary Syndrome (PCOS) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Polycystic Ovary Syndrome (PCOS) Drugs Market Segment Percentages, by Application, 2021 (%)
Global Polycystic Ovary Syndrome (PCOS) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Polycystic Ovary Syndrome (PCOS) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Polycystic Ovary Syndrome (PCOS) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
- Key companies Polycystic Ovary Syndrome (PCOS) Drugs revenues share in global market, 2021 (%)
- Key companies Polycystic Ovary Syndrome (PCOS) Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
- Key companies Polycystic Ovary Syndrome (PCOS) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Sanofi
- Novartis AG
- Teva Pharmaceutical Industries Limited
- Addex Therapeutics Ltd.
- BIOCAD
- Merck KGaA
- AstraZeneca plc.
- Bristol Myers Squibb Co.
- Ferring Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc.
